Phase 2 N=12 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Ewing's Sarcoma
Primary: Objective Response Rate of Olaparib — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=164 Smoking Cessation After Hospitalization for a Cardiopulmonary Illness
Smoking Cessation
Primary: Abstinence From Smoking — 15; 7; 13; 10 percentage of participants
Phase 2 N=89 Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD
COPD
Primary: Change From Baseline in Alveolar Macrophage Expression of Nrf2 and Associated Genes at 4 Weeks — 0.80; 1.03; 0.94; 0.90 fold change — p=0.45
N/A N=240 Comparison Study in Adult Surgical Patients of 5 Airway Devices
Laryngoscopy · Intubation
Primary: Percentage Distribution of Cook's Modification of Cormack-Lehane's Grading System. Each Study Subject Will Receive a Grade of 1, 2A, 2B, 3A, 3B, or 4 in the…
Phase 4 N=29,255 Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
Influenza
Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI
N/A N=42 Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes
Type 1 Diabetes
Primary: Change in HgBA1c — 8.5; 8.7 percentage of glycosylated hemoglobin
Phase 4 N=1,004 Primary Care Intervention Strategy for Anxiety Disorders
Post-traumatic Stress Disorder · Generalized Anxiety Disorder · Panic Disorder
Primary: BSI-12 (Anxiety and Somatization Subscales) — 325; 258 number of responders
Phase 2 N=72 Micronutrients to Prevent Noise-induced Hearing Loss
Noise-Induced Hearing Loss
Primary: Average Threshold Shift at 4 kHz in Both Ears — 3.94; 3.4; 2.77; 2.03 decibels — p=0.58
Phase 2 N=116 Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline at Week 4 in Prostate Specific Antigen (PSA) Concentration. — -0.1; -0.1; -0.3; -0.4 ng/mL — p=0.4678
Phase 3 N=173 Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Mucopolysaccharidosis IV A · Morquio A Syndrome · MPS IVA
Primary: Change From Baseline in 6-minute Walk (6MW) Test - ITT — 219.7; 207.2; 205.7; 203.9 meters
Phase 3 N=1,223 Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Percentage of 12-Week CSBM Overall Responders — 4.7; 13.4; 95.3; 86.6 percentage of participants — p=< 0.0001
Phase 3 N=370 A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.3; -54.2 percent change — p=<0.001
Phase 4 N=106 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Well-differentiated Pancreatic Neuroendocrine Tumor
Primary: Progression-Free Survival (PFS): Investigator Assessment — 13.2; 13.0 months
Phase 2 N=12 Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
Nephrogenic Systemic Fibrosis
Primary: Percentage Change From Baseline in the Modified Rodnan Skin Score (mRSS) to Assess Skin Tethering — -24 percentage change in mRSS score
N/A N=3,345 Modified Instrumentation for Surgery to Correct Trichiasis
Trachoma
Primary: Number of Eyelids With Presence of Recurrent Trichiasis — 948; 1062; 721; 612 eyelids